Form 4: Cabaletta Bio Executive Receives Repriced Stock Options

Michael Gerard, General Counsel of Cabaletta Bio, receives repriced stock options following board approval.

Summary

• Michael Gerard, General Counsel of Cabaletta Bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 19, 2025, Gerard received repriced stock options as part of a board-approved repricing plan effective the same day.
• The repricing affects multiple stock option awards with varying original exercise prices, all adjusted to $1.92 per share, reflecting the fair market value on the repricing date.
• The repriced options are subject to a retention period, where the original exercise price will be reinstated if exercised within one year of the repricing date, upon a sale event, or termination of service due to death or disability.

Sentiment

Score: 6

Explanation: The document itself is neutral, detailing a standard executive compensation adjustment. The sentiment is slightly positive as it suggests efforts to retain key personnel, but the impact on shareholder value is uncertain.

Positives

• The repricing of stock options may incentivize Michael Gerard to remain with Cabaletta Bio.
• The repricing aligns executive compensation with the current market value of the company's stock.

Negatives

• The repricing of stock options could be seen negatively by shareholders if the original option prices were significantly higher, as it dilutes the value of existing shares.
• The retention period introduces complexity to the option exercise terms.

Risks

• If the company's stock price does not increase, the repriced options may not provide the intended incentive.
• The retention period could create uncertainty for the executive regarding the optimal time to exercise the options.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the stock option repricing and vesting schedule.

Industry Context

Stock option repricing is a common practice in the biotech industry to retain key employees, especially when a company's stock price has declined. It aims to re-incentivize employees by adjusting the exercise price to reflect current market conditions.

Comparison to Industry Standards

• Repricing of stock options is a fairly common practice, especially in volatile sectors like biotechnology.
• Many companies use similar retention periods to ensure that executives remain with the company after receiving repriced options.
• The specific terms of the repricing, such as the exercise price and retention period, are generally tailored to the individual executive and the company's specific circumstances.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution of shares due to the repriced options.
• Employees, particularly Michael Gerard, are impacted by the change in incentive structure.
• The repricing could impact the company's financial statements due to changes in stock-based compensation expense.

Key Dates

Keywords

stock options, Cabaletta Bio, repricing, Form 4, Michael Gerard, executive compensation, beneficial ownership